TWI406635B - An additive for lowering cholesterol contents in aquatic animals - Google Patents
An additive for lowering cholesterol contents in aquatic animals Download PDFInfo
- Publication number
- TWI406635B TWI406635B TW99146504A TW99146504A TWI406635B TW I406635 B TWI406635 B TW I406635B TW 99146504 A TW99146504 A TW 99146504A TW 99146504 A TW99146504 A TW 99146504A TW I406635 B TWI406635 B TW I406635B
- Authority
- TW
- Taiwan
- Prior art keywords
- feed
- additive
- cholesterol
- chinese herbal
- aquatic
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 242
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 113
- 241001465754 Metazoa Species 0.000 title claims abstract description 65
- 239000000654 additive Substances 0.000 title claims abstract description 55
- 230000000996 additive effect Effects 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 241000411851 herbal medicine Species 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 238000009360 aquaculture Methods 0.000 claims description 4
- 244000144974 aquaculture Species 0.000 claims description 4
- 241000132012 Atractylodes Species 0.000 claims description 3
- 241000234276 Curculigo Species 0.000 claims description 3
- 241001632410 Eleutherococcus senticosus Species 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 2
- 235000011613 Pinus brutia Nutrition 0.000 claims description 2
- 241000018646 Pinus brutia Species 0.000 claims description 2
- 241000205407 Polygonum Species 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 claims 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 39
- 235000018291 probiotics Nutrition 0.000 abstract description 39
- 230000000529 probiotic effect Effects 0.000 abstract description 27
- 239000000203 mixture Substances 0.000 abstract description 14
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract description 9
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract description 7
- 210000002149 gonad Anatomy 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 5
- 235000016709 nutrition Nutrition 0.000 abstract description 5
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000238557 Decapoda Species 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- 241000251468 Actinopterygii Species 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- 235000019688 fish Nutrition 0.000 description 12
- 210000002969 egg yolk Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 6
- 241000252212 Danio rerio Species 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- 108010089254 Cholesterol oxidase Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108010055297 Sterol Esterase Proteins 0.000 description 4
- 102000000019 Sterol Esterase Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001465318 Aspergillus terreus Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 241000530454 Litopenaeus schmitti Species 0.000 description 3
- 241000238553 Litopenaeus vannamei Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 241000228153 Penicillium citrinum Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012214 genetic breeding Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 2
- 241000733943 Hapalogaster mertensii Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000228145 Penicillium brevicompactum Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 235000021405 artificial diet Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000004060 quinone imines Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- XPQIPNORJZZYPV-UHFFFAOYSA-N 2-hydroxymethylglutaric acid Chemical compound OCC(C(O)=O)CCC(O)=O XPQIPNORJZZYPV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 241001289529 Fallopia multiflora Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 description 1
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- -1 compound compound Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 229940098377 penicillium brevicompactum Drugs 0.000 description 1
- 239000010341 ping gan Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本發明係關於一種可降低水產動物體內膽固醇含量的添加劑,其包括一複合益生菌配方和一中草藥複方組合,單獨使用或合併使用皆可降低水產動物體內膽固醇含量,尤其是可降低該水產動物血清中、肝臟或生殖腺中之膽固醇含量。The invention relates to an additive which can reduce the cholesterol content in an aquatic animal, which comprises a combination of a compound probiotic formula and a Chinese herbal medicine combination, which can reduce the cholesterol content of the aquatic animal, or reduce the serum of the aquatic animal, either alone or in combination. Cholesterol content in the middle, liver or gonads.
隨著人民生活水準的提升,近幾年來高血脂病人明顯增加,血液中的膽固醇過高,就可能會積聚在血管的內壁上,令血管慢慢變得狹窄,甚至可能把血管堵塞,假如這種情況發生在供應血液給心臟肌肉的冠狀動脈,便會引發冠心病;若堵塞的血管在腦部,則會造成中風,目前的疾病殺手排名榜中,中風和心臟病佔很重的比例,已成為全球衛生保健之重要議題。血液中的膽固醇含量經證實與冠狀動脈心臟病(coronary heart disease,CHD)有關,因為它會引起動脈粥樣硬化(Atherosclerosis)。臨床試驗指出,血膽固醇含量每降低1%,冠狀動脈心臟病的發生率將會減少2%。故美國心臟學會推薦每人每日的膽固醇攝取量應少於300mg,否則就應該多攝取富含ω-3脂肪酸,以減少心臟病的衝擊,為因應市場需求,遂有「低膽固醇量」食品的研發。With the improvement of people's living standards, the number of hyperlipidemia patients has increased significantly in recent years, and the cholesterol in the blood is too high, which may accumulate on the inner wall of blood vessels, making the blood vessels gradually narrow, and may even block the blood vessels, if This happens when the coronary arteries that supply blood to the heart muscle cause coronary heart disease; if the blocked blood vessels are in the brain, it will cause a stroke. In the current disease killer rankings, the proportion of stroke and heart disease is very heavy. Has become an important issue in global health care. Cholesterol levels in the blood have been shown to be associated with coronary heart disease (CHD) because it causes atherosclerosis. Clinical trials have shown that for every 1% reduction in blood cholesterol levels, the incidence of coronary heart disease will be reduced by 2%. Therefore, the American Heart Association recommends that each person's daily cholesterol intake should be less than 300mg. Otherwise, they should take more omega-3 fatty acids to reduce the impact of heart disease. In order to meet market demand, there is no "low cholesterol" food. Research and development.
很多常見水產品屬於高膽固醇食品,例如:每100克新鮮白蝦中含膽固醇54毫克,但乾蝦米膽固醇含量就達到434毫克,水發魷魚的膽固醇含量達到308毫克;此外,蟹黃膽固醇高達466毫克,蜆高達454毫克;有高血脂問題的人須有所節制。Many common aquatic products are high-cholesterol foods. For example, every 100 grams of fresh white shrimp contains 54 mg of cholesterol, but the dry shrimp has a cholesterol content of 434 mg, and the watery salmon has a cholesterol content of 308 mg. In addition, crab yellow cholesterol is as high as 466 mg. , 蚬 up to 454 mg; people with high blood lipid problems must be modest.
膽固醇是僅存於動物體內,由Acetyl-CoA經由一連串反應所合成,含27個碳,分子重為386,在動物體內主要以游離態(free cholesterol)和酯化態(cholesterolester)二種方式存在,二者比例因組織不同而異,其在人體中的合成主要位置為肝臟(佔50%)、小腸(佔15%)、其他組織(以皮膚最多,佔35%);在蛋雞中最主要位置為肝臟,而卵巢則只有極微或甚至沒有能力去合成脂蛋白。人體及動物均需要一些膽固醇,以便維持生命及正常生理功能。膽固醇在動物體的生理功能為(1)它是細胞膜的必須成份,可調節細胞膜的流動性,(2)膽固醇是維生素D、膽酸和類固醇內泌素的先質,(3)胚胎發育所需的物質,在自然選拔壓力(Natural selection pressure)下,為維持胚胎發育的營養環境,故造成遺傳選拔無法顯著降低動物中之膽固醇含量(Holland et al.,1980)。Cholesterol is only found in animals. It is synthesized by Acetyl-CoA through a series of reactions. It contains 27 carbons and has a molecular weight of 386. It is mainly present in free cholesterol and cholesterol (cholesterolester). The proportion of the two varies from organization to organization, and the main sites of synthesis in the human body are liver (50%), small intestine (15%), and other tissues (the most skin, accounting for 35%); the most important in laying hens The location is the liver, while the ovaries have little or no ability to synthesize lipoproteins. Both humans and animals need some cholesterol to maintain life and normal physiological functions. The physiological function of cholesterol in animals is (1) it is an essential component of the cell membrane, regulating the fluidity of the cell membrane, (2) cholesterol is the precursor of vitamin D, cholic acid and steroid endocrine, (3) embryo development The required material, under the natural selection pressure, maintains the nutrient environment for embryo development, so genetic selection does not significantly reduce cholesterol levels in animals (Holland et al., 1980).
研究人員曾採用遺傳育種技術、飼料營養和藥物等方式來控制動物卵黃膽固醇含量,結果發現飼料膽固醇和脂肪會增加卵黃膽固醇含量,而飼料纖維含量或某些藥物可以減低卵黃膽固醇含量,但降幅有限,利用遺傳育種技術則並未見成效,或僅能降低5-7%膽固醇,同時產蛋表現亦受到影響,故目前為止,仍是很難以傳統遺傳育種技術作品種改良方式,將生殖腺或卵黃膽固醇含量降低。以飼料營養或藥物來加以調控,則變成動物營養學研究的重心。Researchers have used genetic breeding techniques, feed nutrition and drugs to control the yolk cholesterol content of animals. It has been found that feed cholesterol and fat increase yolk cholesterol content, while feed fiber content or certain drugs can reduce yolk cholesterol content, but the decline is limited. The use of genetic breeding techniques has not yielded results, or only reduced 5-7% cholesterol, and the performance of laying eggs has also been affected. Therefore, it is still difficult to improve the genital gland or yolk by traditional genetic breeding techniques. Reduced cholesterol levels. The regulation of feed nutrition or drugs has become the focus of animal nutrition research.
自從1976年降膽固醇物質(HMG-CoA reducatase inhibitor類)於Penicillium brevicompactum 及P. citrinum 所分離出來後,許多類似的物質就相繼的從Aspergillus與Monascus中分離出來。1979從紅麴菌(Monascus ruber )培養液中分離出monacolin k,同時美國學者亦從Aspergillus terreus 分離出相同化學構造的物質,但命名為mevinolin。1987年Merck公司發展出Lovastatin,並率先製成藥品上市。Lovastatin是紅麴菌Monascus purourous 發酵產物的活性成分,所以monacolin K、mevinolin、Lovastatin均為相同物質。Since the cholesterol-lowering substance (HMG-CoA reducatase inhibitor) was isolated from Penicillium brevicompactum and P. citrinum in 1976 , many similar substances have been separated from Aspergillus and Monascus. In 1979, monacolin k was isolated from the culture of Monascus ruber , and American scholars also isolated the same chemical structure from Aspergillus terreus , but named mevinolin. In 1987, Merck developed Lovatatin and was the first to market its drug. Lovastatin is the active ingredient of the fermentation product of Monascus purourous , so monacolin K, mevinolin and lovastatin are all the same.
複合益生菌群所產生的抗氧化物質與生物活性成分可降低雞蛋中膽固醇的含量。研究發現給30周齡的羅曼蛋雞餵食複合益生菌群發酵的飼料,結果全蛋可食部分蛋白質提高了10-13%、脂肪降低了11.7%,膽固醇下降了15-91%。由於複合益生菌群具有高選擇性地為動物腸道內雙歧桿菌等有益菌提供培養基質,而刺激該有益菌迅速大量增殖的功能,而雙歧桿菌和乳桿菌等有益菌,在動物體內能夠合成多種維生素,如葉酸、煙酸、維生素B1、B2和B6等,可促進動物對蛋白質、鈣、鋅和鐵等營養的吸收,顯著地提高動物生產性能。The antioxidants and bioactive ingredients produced by the complex probiotics can reduce the cholesterol content of the eggs. The study found that 30-week-old roman hens were fed a diet fed with a combination of probiotics. As a result, the total protein of the whole egg increased by 10-13%, fat decreased by 11.7%, and cholesterol decreased by 15-91%. Since the compound probiotics group has high selectivity to provide a culture medium for beneficial bacteria such as bifidobacteria in the intestinal tract of the animal, and stimulates the rapid proliferation of the beneficial bacteria, the beneficial bacteria such as bifidobacteria and lactobacilli are in the animal body. It can synthesize a variety of vitamins, such as folic acid, niacin, vitamins B1, B2 and B6, which can promote the absorption of nutrients such as protein, calcium, zinc and iron, and significantly improve animal performance.
由於中草藥添加劑具有促進動物生長、增強其抵抗力、毒性副作用低、無藥物殘留、不易產生抗藥性等特點,近年來備受飼料業重視。Because Chinese herbal medicine additives have the characteristics of promoting animal growth, enhancing their resistance, low toxicity and side effects, no drug residues, and low resistance to drug resistance, they have received much attention in the feed industry in recent years.
研究發現用紅麴、金銀花、杜仲、水飛薊、山柞等中草藥組成複方製劑,按500mg/kg和250mg/kg的劑量分別添加於32周齡尼克紅蛋雞的日糧中,結果發現,蛋黃中膽固醇的濃度(mg/g蛋黃)比對照組分別下降了25.4%(P<0.05)和17.4%(P<0.05);血漿膽固醇、LDL-C、VLDL濃度降低顯著(P<0.01),且提高了HDL濃度;改善了雞蛋脂肪的組成,亞油酸的含量分別提高24.2%。17.1%;亞麻酸的含量升高44%和36%。另有研究發現,在280日齡羅曼蛋雞日糧中分別添加1%由絞股藍等中草藥組成的平肝散和1.5%由辣椒、石膏、絞股藍等組成的加味紅白散,試驗表明,試驗組分別比對照組雞蛋膽固醇含量降低15.45%和14.81%。The study found that a compound preparation consisting of Chinese herbal medicines such as red peony, honeysuckle, eucommia, silybum, hawthorn, etc., was added to the diet of 32-week-old Nickel hens at doses of 500 mg/kg and 250 mg/kg, respectively. The concentration of cholesterol in egg yolk (mg/g egg yolk) decreased by 25.4% (P<0.05) and 17.4% (P<0.05), respectively. The plasma cholesterol, LDL-C and VLDL concentrations decreased significantly (P<0.01). And increased the HDL concentration; improved the composition of egg fat, the content of linoleic acid increased by 24.2%. 17.1%; the content of linolenic acid increased by 44% and 36%. Another study found that in the 280-day-old Roman chicken laying hen diet, 1% of Pinggan powder consisting of Chinese herbal medicines such as Gynostemma pentaphyllum and 1.5% of flavored red and white powder consisting of pepper, gypsum and Gynostemma pentaphyllum were added. Compared with the control group, the cholesterol content of eggs decreased by 15.45% and 14.81%.
綜合上述,雖已有應用複合益生菌群或中草藥於降低雞蛋中膽固醇的技術,然而目前尚未有應用於降低水產動物體內膽固醇之技術發現,且禽類與水產類飼料製作與應用技術差異很大,而許多水產動物,如魚類,蝦類,蟹類,貝類等,其中膽固醇含量高又是許多饕客的最愛,為了能兼顧美味與健康,提升水產養殖產業品質,是以,本案發明人,乃亟思加以改良創新,並經多年苦心孤詣潛心研究後,終於成功研發完成本件一種降低水產動物體內膽固醇含量的添加劑。In summary, although there are techniques for reducing cholesterol in eggs by using a combination of probiotics or Chinese herbal medicines, there have been no technical discoveries for reducing cholesterol in aquatic animals, and the production and application techniques of poultry and aquatic products vary greatly. Many aquatic animals, such as fish, shrimps, crabs, shellfish, etc., which have high cholesterol content, are the favorite of many hackers. In order to balance the taste and health and improve the quality of the aquaculture industry, the inventor of this case is After thinking and improving, and after many years of painstaking research, I finally succeeded in research and development of this kind of additive to reduce the cholesterol content of aquatic animals.
本發明之目的為提供一種降低水產動物體內膽固醇含量的添加劑,其中包括一複合益生菌配方,可用來降低水產動物體內之膽固醇含量。It is an object of the present invention to provide an additive which reduces cholesterol levels in aquatic animals, including a compound probiotic formulation which can be used to reduce cholesterol levels in aquatic animals.
本發明之另一目的為提供一種降低水產動物體內膽固醇含量的添加劑,其中包括一中草藥複方組合,可用來降低水產動物體內之膽固醇含量。Another object of the present invention is to provide an additive for reducing the cholesterol content of aquatic animals, which comprises a combination of Chinese herbal medicines, which can be used to reduce the cholesterol content in aquatic animals.
本發明之目的為提供一種降低水產動物體內膽固醇含量的添加劑,其中包括上述一複合益生菌配方及一中草藥複方組合,合併使用可用來降低水產動物體內之膽固醇含量。The object of the present invention is to provide an additive for reducing the cholesterol content in aquatic animals, which comprises the above-mentioned compound probiotic formula and a combination of Chinese herbal medicines, which can be used to reduce the cholesterol content in aquatic animals.
本發明之另一目的為提供水產飼料添加之方法:其中包括Another object of the present invention is to provide a method of adding aquafeed: including
將上述複合益生菌配方以0.5%以上重量比(添加劑/飼料,W/W),均勻噴灑在人工水產飼料上,靜置5分鐘以上使其完全吸收後,置於暗處進行發酵,之後投餵於水產動物。The above composite probiotic formula is uniformly sprayed on the artificial aquatic feed at a weight ratio of 0.5% or more (additive/feed, W/W), allowed to stand for more than 5 minutes to be completely absorbed, and then placed in a dark place for fermentation, and then cast. Feed to aquatic animals.
取上述複合益生菌配方與生餌飼料之重量比為0.5%以上(添加劑/飼料,W/W),添加至生餌中均勻混合,靜置10分鐘以上讓生餌與該添加劑黏附完全後投餵;其中該生餌為新鮮的魚蝦碎肉。Take the weight ratio of the above composite probiotics formula to the raw bait feed by 0.5% or more (additive/feed, W/W), add to the raw bait and mix evenly, let stand for more than 10 minutes, let the raw bait adhere to the additive and then cast. Feed; the raw bait is fresh fish and minced meat.
取上述中草藥複方組合,以0.5%以上重量比(添加劑/飼料,W/W)加入人工水產飼料中預拌均勻,投餵時全程使用此飼料。Take the above combination of Chinese herbal medicine, add 0.5% or more by weight (additive/feed, W/W) to the artificial aquatic feed and mix well. Use this feed throughout the feeding.
取上述中草藥複方組合,以0.5%以上重量比(添加劑/飼料,W/W),加入生餌飼料中混合均勻,靜置10分鐘以上讓生餌與該添加劑黏附完全後投餵;其中該生餌為新鮮的魚蝦碎肉。Take the above combination of Chinese herbal medicine, add 0.5% or more by weight (additive/feed, W/W), mix it into the raw bait feed, and let it stand for more than 10 minutes to let the raw bait adhere to the additive and then feed it; The bait is fresh fish and shrimp.
取該複合益生菌配方0.5%以上重量比(添加劑/飼料,W/W),均勻噴灑在人工飼料上,靜置5分鐘以上使完全吸收後,置於暗處進行發酵;再將上述之中草藥複方組合以0.5%重量比(添加劑/飼料,W/W)加入人工飼料中預拌均勻,投餵時全程使用此專門飼料。Take more than 0.5% by weight of the compound probiotic formula (additive/feed, W/W), spray it evenly on the artificial diet, let it stand for more than 5 minutes to completely absorb it, and then put it in the dark place for fermentation; The compound combination is added to the artificial feed at a ratio of 0.5% by weight (additive/feed, W/W), and the mixture is uniformly mixed. The special feed is used throughout the feeding.
將該複合益生菌配方及上述之中草藥複方組合粉料各以0.5%重量比(添加劑/飼料,W/W)添加至生餌中均勻混合,靜置10分鐘以上讓生餌與該添加劑黏附完全後投餵。The composite probiotic formula and the above-mentioned herbal compound combination powder are added to the raw bait uniformly in a ratio of 0.5% by weight (additive/feed, W/W), and allowed to stand for more than 10 minutes to completely adhere the raw bait to the additive. After feeding.
為達上述目的,本發明所述之一種降低水產動物體內膽固醇含量的添加劑,其中包括一複合益生菌配方,其中該複合益生菌配方以複合性微生物製劑(Complex Beneficial Microorganisms,CBM)為基礎配方,其中包含一種或一種以上之光合細菌、乳酸菌、酵母菌、放線菌及含降低膽固醇物質之特殊菌種等微生物,其中含降低膽固醇物質之特殊菌種係選自一種或一種以上之下列菌種:P. brevicompac tum、P. citrinum、A.terreus、M. purourous 及M. ru ber,通過共棲培養技術發酵培養而成。該複合益生菌配方有幾項優點:(1)由於單一菌種難以保存,利用該複合益生菌配方可長期保存與擴增產生降膽固醇物質Monacolin K之特殊菌種;(2)藉由各益生菌產生的抗氧化物質、生物活性物質(bioactive compounds)可降低水產動物中膽固醇的含量,例如乳酸菌產生的羥甲基戊二酸輔酶A還原酶、乳清酸、鈣、乳糖等,酵母菌產生的煙酸等,對降低動物中膽固醇都起了重要作用;(3)具有高選擇性地為動物腸道內雙歧桿菌等有益菌提供培養基質,而刺激該有益菌迅速大量增殖的功能,而雙歧桿菌和乳桿菌等有益菌,在動物體內能夠合成多種維生素,如葉酸、煙酸、維生素B1、B2和B6等,可促進動物對蛋白質、鈣、鋅和鐵等營養的吸收,顯著地提高動物生產性能;(4)利用該複合益生菌配方降低水產動物體內膽固醇後,對該動物生殖腺的營養價值和性質沒有發生明顯的變化。To achieve the above object, an additive for reducing cholesterol content in an aquatic animal according to the present invention comprises a composite probiotic formulation, wherein the composite probiotic formulation is based on Complex Beneficial Microorganisms (CBM). The invention comprises one or more microorganisms such as photosynthetic bacteria, lactic acid bacteria, yeast, actinomycetes and special bacteria containing cholesterol-lowering substances, wherein the special bacterial species containing the cholesterol-lowering substances are selected from one or more of the following species: P. brevicompac tu m, P. citrinum, A. terreus, M. purourous and M. ru ber, fermented by commensal culture techniques. The compound probiotic formula has several advantages: (1) because the single strain is difficult to preserve, the compound probiotic formula can be used for long-term preservation and amplification of the special strain of the cholesterol-lowering substance Monacolin K; (2) by each probiotic Antioxidant substances and bioactive compounds produced by bacteria can reduce the content of cholesterol in aquatic animals, such as hydroxymethylglutaric acid coenzyme A reductase produced by lactic acid bacteria, orotic acid, calcium, lactose, etc. Niacin, etc., plays an important role in reducing cholesterol in animals; (3) it has a high selectivity to provide a culture medium for beneficial bacteria such as bifidobacteria in the intestinal tract of animals, and stimulates the rapid proliferation of the beneficial bacteria. Bifidobacteria and Lactobacillus can produce a variety of vitamins, such as folic acid, niacin, vitamins B1, B2 and B6, which can promote the absorption of protein, calcium, zinc and iron. To improve animal performance; (4) After using the compound probiotic formula to reduce cholesterol in aquatic animals, the nutritional value and properties of the gonads of the animal did not appear obvious. Variety.
人類與水產類生理結構大為不同,因此雖已知中草藥可降低人體內血脂與膽固醇,但尚未證實是否也可應用於水產動物,故本發明將證實該中草藥複方組合可降低水產動物體內之膽固醇含量。Human and aquatic physiological structures are very different. Therefore, although Chinese herbal medicines are known to reduce blood lipids and cholesterol in humans, it has not been confirmed whether it can also be applied to aquatic animals. Therefore, the present invention will prove that the Chinese herbal compound combination can lower cholesterol in aquatic animals. content.
中草藥可降低人體內血脂與膽固醇之機轉為:(1)促進腸道膽固醇的排泄,抑制外源性膽固醇的吸收;(2)競爭性地抑制腸道膽固醇吸收;(3)抑制膽固醇、三酸甘油酯的體內合成;(4)影響血脂的分佈、運轉與清除;以及(5)促進膽固醇的分解與排泄。根據上述中草藥降血脂與膽固醇的機轉,本發明人配製一中草藥複方組合,其中包括黨參、白術、刺五加、仙茅、何首烏、當歸、艾葉、山楂、神曲、麥芽與松針細末。將該中草藥複方組合與飼料以重量比0.5%以上之比例混合均勻後餵食水產動物。Chinese herbal medicine can reduce the body's blood lipids and cholesterol into: (1) promote intestinal cholesterol excretion, inhibit the absorption of exogenous cholesterol; (2) competitive inhibition of intestinal cholesterol absorption; (3) inhibition of cholesterol, three In vivo synthesis of glycerides; (4) affecting the distribution, functioning and clearance of blood lipids; and (5) promoting the decomposition and excretion of cholesterol. According to the above-mentioned herbal medicine to reduce blood fat and cholesterol, the inventors formulated a combination of Chinese herbal medicine, including Codonopsis pilosula, Atractylodes, Acanthopanax senticosus, Curculigo, Polygonum, Angelica, Ai, Hawthorn, Divine Comedy, Malt and Pinus fine. The herbal combination of the Chinese herbal medicine and the feed are uniformly mixed at a ratio of 0.5% by weight or more, and then the aquatic animal is fed.
本發明係以下面的實施例予以示範闡明,但本發明不受下述實施例所限制。The present invention is exemplified by the following examples, but the present invention is not limited by the following examples.
複合益生菌配方係以複合性微生物製劑(Complex Beneficial Microorganisms,CBM)為基礎配方,其中包含一種或一種以上之光合細菌、乳酸菌、酵母菌、放線菌及含降低膽固醇物質之特殊菌種等微生物,其中含降低膽固醇物質之特殊菌種係選自一種或一種以上之下列菌種:P. brevicompac tum、P. citrinum 、A.terreus 、M. purourous 及M. ru ber,通過共棲培養技術發酵培養而成。The compound probiotic formula is based on Complex Beneficial Microorganisms (CBM), which contains one or more microorganisms such as photosynthetic bacteria, lactic acid bacteria, yeasts, actinomycetes, and special strains containing cholesterol-lowering substances. The special strain containing cholesterol-lowering substances is selected from one or more of the following strains: P. brevicompac tum, P. citrinum , A. terreus , M. purourous and M. ru ber, fermented by commensal culture techniques to make.
人類與水產類生理結構大為不同,因此雖已知中草藥可降低人體內血脂與膽固醇(如下表所示,代表有功效),但尚未證實是否也可應用於水產動物,故本發明將證實該中草藥複方組合可降低水產動物體內之膽固醇含量:Humans and aquatic structures are very different, so it is known that Chinese herbal medicines can lower blood lipids and cholesterol in humans (as shown in the table below, The representative has efficacy), but it has not been confirmed whether it can also be applied to aquatic animals, so the present invention will prove that the Chinese herbal compound combination can reduce the cholesterol content in aquatic animals:
根據上述中草藥降血脂與膽固醇的機轉,本發明人配製一中草藥複方組合包含黨參與白術各50~150克、刺五加、仙茅、何首烏、當歸與艾葉各30~150克、山楂、神曲與麥芽各20~150克與松針細末100~300克,混合均勻後添加至飼料中,其添加量為飼料總重量之0.5%以上。According to the above-mentioned Chinese herbal medicine to reduce blood fat and cholesterol, the inventors formulated a Chinese herbal compound combination comprising 50 to 150 grams of the party participating in Atractylodes, Acanthopanax senticosus, Curculigo, Polygonum multiflorum, Angelica and Ai Ye each 30 to 150 grams, Hawthorn, Divine Comedy 20 to 150 grams of malt and 100 to 300 grams of pine needles are mixed and added to the feed, and the added amount is 0.5% or more of the total weight of the feed.
取該複合益生菌配方0.5%以上重量比(添加劑/飼料,W/W),均勻噴灑在人工水產飼料上,靜置5分鐘使其完全吸收後,置於黑色塑膠袋或有蓋的塑膠桶進行1~2天之發酵,之後投餵於水產動物。Take more than 0.5% by weight of the compound probiotic formula (additive/feed, W/W), spray it evenly on the artificial aquatic feed, let it stand for 5 minutes, completely absorb it, and put it in a black plastic bag or a covered plastic bucket. Fermentation for 1 to 2 days, followed by feeding to aquatic animals.
取該複合益生菌配方與生餌飼料之重量比為0.5%以上(添加劑/飼料,W/W),添加至生餌中均勻混合,靜置15分鐘讓生餌與該添加劑黏附完全後投餵;其中該生餌為新鮮的魚蝦碎肉。The weight ratio of the compound probiotics to the raw bait feed is 0.5% or more (additive/feed, W/W), added to the raw bait and uniformly mixed, and allowed to stand for 15 minutes to allow the raw bait to adhere to the additive and then feed. Where the raw bait is fresh fish and minced meat.
取上述中草藥複方組合,以0.5%以上重量比(添加劑/飼料,W/W)加入人工水產飼料中預拌均勻,投餵時全程使用此飼料。Take the above combination of Chinese herbal medicine, add 0.5% or more by weight (additive/feed, W/W) to the artificial aquatic feed and mix well. Use this feed throughout the feeding.
取上述中草藥複方組合,以0.5%以上重量比(添加劑/飼料,W/W),加入生餌飼料中混合均勻,靜置15分鐘讓生餌與該添加劑黏附完全後投餵;其中該生餌為新鮮的魚蝦碎肉。Take the above combination of Chinese herbal medicine, add 0.5% or more by weight (additive/feed, W/W), mix it into the raw bait feed, and let it stand for 15 minutes to let the raw bait adhere to the additive and then feed it; Minced meat for fresh fish and shrimp.
取該複合益生菌配方0.5%以上重量比(添加劑/飼料,W/W),均勻噴灑在人工飼料上,靜置5分鐘使完全吸收後,置於黑色塑膠袋或有蓋的塑膠桶進行1~2天之發酵;再將上述之中草藥複方組合以0.5%重量比(添加劑/飼料,W/W)加入人工飼料中預拌均勻,投餵時全程使用此專門飼料。Take the compound probiotic formula 0.5% or more by weight (additive/feed, W/W), spray it evenly on the artificial feed, let it stand for 5 minutes to completely absorb it, and put it in a black plastic bag or a covered plastic bucket for 1~ 2 days of fermentation; the above combination of Chinese herbal medicine is added to the artificial feed with 0.5% by weight (additive/feed, W/W), and the mixture is evenly mixed, and the special feed is used throughout the feeding.
將該複合益生菌配方及上述之中草藥複方組合各以0.5%重量比(添加劑/飼料,W/W)添加至生餌中均勻混合,靜置15分鐘讓生餌與該添加劑黏附完全後投餵。The composite probiotic formula and the above-mentioned herbal combination are added to the raw bait uniformly in a ratio of 0.5% by weight (additive/feed, W/W), and allowed to stand for 15 minutes to allow the raw bait to adhere to the additive and then fed. .
以上述含添加劑飼料餵食水產動物1~2個月後,檢測該水產動物體內膽固醇含量。After the aquatic animals were fed with the above additive-containing feed for 1 to 2 months, the cholesterol content of the aquatic animal was measured.
以上述含添加劑飼料餵食水產動物1~2個月後,檢測該水產動物體內膽固醇含量。After the aquatic animals were fed with the above additive-containing feed for 1 to 2 months, the cholesterol content of the aquatic animal was measured.
配合下列兩種方式以測定動物血清、肌肉,魚卵或卵巢(蟹膏)、精巢(蟹黃)之膽固醇含量;未成熟動物則採用肝胰臟來測定總膽固醇含量。The following two methods are used to determine the cholesterol content of animal serum, muscle, fish eggs or ovary (crab cream), testis (crab); immature animals use hepatopancreas to determine total cholesterol.
總膽固醇測定原理與方法Principles and methods for determination of total cholesterol
膽固醇酯(cholesterol ester)在膽固醇酯酶(cholesterase,CHE)作用下水解為游離膽固醇和脂肪酸,膽固醇在膽固醇氧化酶(cholesterol oxidase,COD)作用下,生成Δ4-膽甾烯酮(cholest-4-en-3-one)和過氧化氫(H2 O2 ),而H2 O2 經過氧化物酶(Peroxidase,POD)作用在4-氨基安替比林(4-AAP)及苯酚參與下,生成紅色醌亞胺色素。在波長500nm處測定溶液吸光度,醌亞胺色素吸光度與樣品中膽固醇含量成正比。Cholesterol ester is hydrolyzed to free cholesterol and fatty acid by cholesterol esterase (CHE), and cholesterol is produced by cholesterol oxidase (COD) to form Δ4-cholestenone (cholest-4- En-3-one) and hydrogen peroxide (H 2 O 2 ), while H 2 O 2 is subjected to the action of peroxidase (POD) in the presence of 4-aminoantipyrine (4-AAP) and phenol. A red quinone imine pigment is formed. The absorbance of the solution was measured at a wavelength of 500 nm, and the absorbance of the quinone imine pigment was directly proportional to the cholesterol content in the sample.
取0.5克組織加入9ml冷卻萃取液(氯仿(cholorform):甲醇(methanol)=2:1;v/v),均質後以轉速3,500rpm離心10分鐘,吸取上清液後保存於4℃;取500ul的組織萃取液,將有機溶劑揮發後,加入等體積的DMSO,以膽固醇檢驗套組(Fortress Diagnostics,UK)測定膽固醇含量。0.5 g of tissue was added to 9 ml of cooling extract (cholorform: methanol = 2:1; v / v), homogenized, centrifuged at 3,500 rpm for 10 minutes, and the supernatant was aspirated and stored at 4 ° C; After 500 ul of tissue extract, the organic solvent was evaporated, an equal volume of DMSO was added, and the cholesterol content was determined using a cholesterol test kit (Fortress Diagnostics, UK).
以抗凝血劑潤洗過之針筒抽取動物血液約5CC,於轉速5,000rpm,4℃下離心25分鐘後吸取上清液,取10ul樣品加入1000ul試劑,於37℃下作用5分鐘後,在500nm波長下測其吸光值,並藉由標準品濃度換算總膽固醇含量;其中該試劑組成為Good’s緩衝液,pH6.7,50mmol/L;酚,5mmol/L;4-氨基安替比林,0.3mmol/L;膽固醇酯酶(CHE),200U/L;膽固醇氧化酶(CHO),50U/L;過氧化物酶(POD),3000U/L。The blood of the animal was extracted with an anticoagulant-washed syringe for about 5 cc. After centrifugation at 5,000 rpm and 4 ° C for 25 minutes, the supernatant was aspirated, and 10 ul of the sample was added to 1000 ul of the reagent, and the solution was applied at 37 ° C for 5 minutes. The absorbance was measured at a wavelength of 500 nm, and the total cholesterol content was converted by standard concentration; wherein the reagent composition was Good's buffer, pH 6.7, 50 mmol/L; phenol, 5 mmol/L; 4-aminoantipyrine , 0.3 mmol/L; cholesterol esterase (CHE), 200U/L; cholesterol oxidase (CHO), 50 U/L; peroxidase (POD), 3000U/L.
將斑馬魚分成兩組飼養,控制組餵食一般飼料,而另一組則餵食添加中草藥複方組合的飼料,各餵食一個月後,分別採集50隻斑馬魚之卵黃測量其中膽固醇之含量。實驗結果顯示以該中草藥配方添加人工飼料後,與對照組相比,可降低魚卵中膽固醇含量(如表一所示)。The zebrafish were divided into two groups. The control group was fed with normal feed, while the other group was fed with a combination of Chinese herbal medicine. After one month of feeding, the yolk of 50 zebrafish was collected to measure the cholesterol content. The experimental results showed that the artificial diet was added to the Chinese herbal medicine formula, and the cholesterol content in the fish eggs was reduced compared with the control group (as shown in Table 1).
將斑馬魚分成四組飼養,控制組餵食一般飼料,而實驗組則分別只餵食添加中草藥複方組合的飼料、加入複合益生菌的飼料組及加入複合一生菌及中草藥複方組,各餵食二星期後,分別採集50隻斑馬魚之卵黃測量其中膽固醇之含量。The zebrafish were divided into four groups, the control group was fed with general feed, while the experimental group was fed only with the combination of the Chinese herbal compound, the feed group with the probiotics, and the compound and Chinese herbal compound group, each feeding for two weeks. The yolk of 50 zebrafish was collected to measure the cholesterol content.
其實驗結果發現,只餵食一般飼料之控制組魚卵得膽固醇含量為2.133mg/dl;將斑馬魚餵食添加中草藥複方飼料組,魚卵中膽固醇含量為2.091 mg/dl;餵食加入複合益生菌之飼料後,發現魚卵中膽固醇含量降為1.739mg/dl;且餵食加入複合益生菌及中草藥複方之飼料組,魚卵中膽固醇含量下降最多,其含量為1.723mg/dl(如圖三所示)。The experimental results showed that the control group of only the general feed had a cholesterol content of 2.133 mg / dl; the zebrafish was fed with the Chinese herbal compound feed group, the cholesterol content of the fish eggs was 2.091 mg / dl; feeding with compound probiotics After the feed, the cholesterol content in the fish eggs was found to be 1.739mg/dl; and the feed group added with the compound probiotics and the Chinese herbal compound compound, the cholesterol content of the fish eggs decreased the most, and its content was 1.723mg/dl (as shown in Figure 3). ).
將南美白蝦分成三組餵養,其中控制組餵食一般飼料;處理組T1以添加複合益生菌配方及中草藥複方組合的飼料餵食;處理組T2則以添加中草藥複方組合的飼料餵食,經過一個月後測量體內膽固醇含量,結果顯示不僅可降低南美白蝦(L. vannamei )血清中膽固醇含量約15%以上(如表二所示);亦可降低其肝胰臟膽固醇含量約20%以上(如表三所示)。The South American white shrimps were divided into three groups, wherein the control group was fed with general feed; the treatment group T1 was fed with a combination of a combination of a probiotic formula and a Chinese herbal compound; and the treatment group T2 was fed with a combination of a Chinese herbal compound, after one month. Measuring the body's cholesterol content, the results show that not only can reduce the serum cholesterol content of South American white shrimp ( L. vannamei ) about 15% or more (as shown in Table 2); it can also reduce the liver and pancreas cholesterol content of about 20% or more (such as Three shows).
處理組T1:複合益生菌配方及中草藥複方組合Treatment group T1: compound probiotic formula and Chinese herbal compound combination
處理處T2:中草藥複方組合Treatment site T2: Chinese herbal compound combination
處理組T1:複合益生菌配方及中草藥複方組合Treatment group T1: compound probiotic formula and Chinese herbal compound combination
處理處T2:中草藥複方組合Treatment site T2: Chinese herbal compound combination
將大閘蟹公蟹分成兩組養殖,其中控制組餵食一般飼料;另一組則餵食添加複合益生菌配方的飼料,養殖一個月後,各組分別隨機收集3~5隻大閘蟹公蟹,測量體內膽固醇含量。實驗結果發現以上述添加劑之人工飼料餵食後,可明顯降低大閘蟹公蟹膽固醇含量約40%以上(表四)The crabs were divided into two groups, the control group was fed with general feed; the other group was fed with feed supplemented with probiotic formula. After one month of culture, each group randomly collected 3~5 male crabs and measured cholesterol in the body. content. The experimental results showed that after feeding with the artificial feed of the above additives, the cholesterol content of hairy crabs was significantly reduced by more than 40% (Table 4).
將大閘蟹母蟹分成兩組養殖,其中控制組餵食一般飼料;另一組則餵食添加複合益生菌配方和中草藥複方組合的飼料,養殖一個月後,各組分別隨機收集3~5隻大閘蟹母蟹,測量體內膽固醇含量。實驗結果發現以上述添加劑之人工飼料餵食後,可明顯降低母蟹卵巢中膽固醇含量約為20%以上(表五)。The crabs were divided into two groups, of which the control group was fed with general feed; the other group was fed with a combination of a combination of probiotics and a combination of Chinese herbal medicines. After one month of culture, each group randomly collected 3 to 5 crabs. , measuring the body's cholesterol content. The experimental results showed that after feeding with the artificial feed of the above additives, the cholesterol content in the ovary of the female crab was significantly reduced by about 20% (Table 5).
本發明試驗測定結果亦表明,該降低水產動物體內膽固醇含量的添加劑可明顯降低水產動物體內膽固醇的含量,且對水產動物生殖腺(精卵)的營養價值和性質沒有發生明顯的變化。The test results of the present invention also show that the additive for lowering the cholesterol content in aquatic animals can significantly reduce the cholesterol content in aquatic animals, and there is no significant change in the nutritional value and properties of the gonads (sperm eggs) of aquatic animals.
上列詳細說明係針對本發明之一可行實施例之具體說明,惟該實施例並非用以限制本發明之專利範圍,凡未脫離本發明技藝精神所為之等效實施或變更,例如:該添加劑可降低其他水產動物如魚類,蝦類,蟹類等體內膽固醇等變化之等效性實施例,均應包含於本案之專利範圍中。The detailed description of the above is a detailed description of a possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the invention, and the equivalents or modifications, such as the additive, are not departing from the spirit of the invention. Equivalent examples of changes in cholesterol in other aquatic animals such as fish, shrimps, crabs, etc., should be included in the patent scope of this case.
綜上所述,本案不但在方法型態上確屬創新,並能較習用物品增進上述多項功效,應已充分符合新穎性及進步性之法定發明專利要件,爰依法提出申請,懇請 貴局核准本件發明專利申請案,以勵發明,至感德便。In summary, this case is not only innovative in terms of method and form, but also can enhance the above-mentioned multiple functions compared with conventional articles. It should fully comply with the statutory invention patent requirements of novelty and progressiveness, and apply for it according to law. This invention patent application, in order to invent invention, to the sense of virtue.
圖一、一種降低水產動物體內膽固醇含量的添加劑可降低南美白蝦(L. vannamei )血清膽固醇含量圖。其中X軸為組別,Y軸為膽固醇含量,單位為mg/dg。處理組T1為餵食添加複合益生菌配方及中草藥複方組合之飼料;處理處T2為餵食添加中草藥複方組合之飼料。Figure 1. An additive that reduces the cholesterol content of aquatic animals can reduce the serum cholesterol level of L. vannamei . The X axis is the group, and the Y axis is the cholesterol content, and the unit is mg/dg. The treatment group T1 is a feed supplemented with a compound probiotic formula and a Chinese herbal compound combination; the treatment T2 is a feed supplemented with a Chinese herbal compound combination.
圖二、一種降低水產動物體內膽固醇含量的添加劑可降低南美白蝦(L. vannamei )肝胰臟膽固醇含量圖。其中X軸為組別,Y軸為膽固醇含量,單位為mg/dg。處理組T1為餵食添加複合益生菌配方及中草藥複方組合之飼料;處理處T2為餵食添加中草藥複方組合之飼料。Figure 2. An additive that reduces the cholesterol content of aquatic animals reduces the cholesterol content of the liver and pancreas of L. vannamei . The X axis is the group, and the Y axis is the cholesterol content, and the unit is mg/dg. The treatment group T1 is a feed supplemented with a compound probiotic formula and a Chinese herbal compound combination; the treatment T2 is a feed supplemented with a Chinese herbal compound combination.
圖三、一種降低水產動物體內膽固醇含量的添加劑可降低斑馬魚卵之膽固醇含量圖。其中X軸為組別,Y軸為膽固醇含量,單位為mg/dl。Figure 3. An additive that reduces the cholesterol content of aquatic animals reduces the cholesterol content of zebrafish eggs. The X axis is the group, and the Y axis is the cholesterol content, and the unit is mg/dl.
圖四、一種降低水產動物體內膽固醇含量的添加劑可降低大閘蟹卵巢膽固醇含量圖。其中X軸為組別,Y軸為膽固醇含量,單位為mg/dg。Figure 4. An additive that reduces the cholesterol content of aquatic animals can reduce the cholesterol content of irritans in hairy crabs. The X axis is the group, and the Y axis is the cholesterol content, and the unit is mg/dg.
圖五、一種降低水產動物體內膽固醇含量的添加劑可降低大閘蟹公蟹膽固醇含量圖。其中X軸為組別,Y軸為膽固醇含量,單位為mg/dg。Figure 5. An additive that reduces the cholesterol content of aquatic animals can reduce the cholesterol content of crabs. The X axis is the group, and the Y axis is the cholesterol content, and the unit is mg/dg.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW99146504A TWI406635B (en) | 2010-12-29 | 2010-12-29 | An additive for lowering cholesterol contents in aquatic animals |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW99146504A TWI406635B (en) | 2010-12-29 | 2010-12-29 | An additive for lowering cholesterol contents in aquatic animals |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201225850A TW201225850A (en) | 2012-07-01 |
TWI406635B true TWI406635B (en) | 2013-09-01 |
Family
ID=46932515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW99146504A TWI406635B (en) | 2010-12-29 | 2010-12-29 | An additive for lowering cholesterol contents in aquatic animals |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI406635B (en) |
-
2010
- 2010-12-29 TW TW99146504A patent/TWI406635B/en not_active IP Right Cessation
Non-Patent Citations (3)
Title |
---|
何謂複合益生菌?對魚塭的好處是???,2010-12-11,網址;http://sumitanitw.pixnet.net/blog/post/23148589 * |
沈松茂,紅麴菌的研發與養生,2008-02-26,網址;http://webcache.googleusercontent.com/search?q=cache:YY8K4qMnEaIJ:www.fandb.com.tw/blog/default.asp%3Fid%3D40+P.+brevicompactum+or+P.+citrinum+or+A.+terreus+or+M.+purourous+or+M.+ruber&cd=1&hl=zh-TW& ct=clnk&gl=tw * |
王興強、葉建生、馬甡、閻斌倫,中草藥制劑在對蝦養殖中的應用,海洋科學/2008年/第32卷/第7期 * |
Also Published As
Publication number | Publication date |
---|---|
TW201225850A (en) | 2012-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4704377B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
CN101095461B (en) | Method for producing selenium-riched low-cholesterol eggs and the products thereof | |
AU2020104245A4 (en) | A Biological Fermentation Preparation and Its Preparation Method | |
TWI627959B (en) | Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual | |
CN103210080A (en) | Yeast strains and their uses in the production of lipids | |
CN103416585B (en) | Broiler chicken probiotics is utilized to improve the method for meat chicken production performance and chicken meat quality | |
CN103421720B (en) | Broiler chicken composite fungus agent and the application in raising meat chicken production performance and immune performance thereof | |
CN102613398B (en) | An additive for reducing cholesterol content in aquatic animals | |
CN104738340A (en) | Method for improving chicken quality of broiler chicken by employing micro-ecological preparation for broiler chicken | |
TW202034934A (en) | The reducing body fat strain, composition thereof and use thereof | |
TWI406635B (en) | An additive for lowering cholesterol contents in aquatic animals | |
CN101791041A (en) | Functional poultry feed additive | |
JP5800327B2 (en) | Uncoupling protein expression inducer | |
Hasibuan et al. | The effect of herbal extracts and probiotic feeding on productivity and quality of broilers | |
EP3756472A1 (en) | Application of schizochytrium limacinum and preparation thereof in improvement of quality and yield of animal product | |
JPH0912466A (en) | Lipid absorption inhibitor / excretion enhancer and high fat food | |
TW202402268A (en) | Composition for improving vascular endothelial function | |
Ayyat et al. | EVALUATION OF POWERTOP® AS GROWTH ENHANCER OF NILE TILAPIA (OREOCHROMIS NILOTICUS) FINGERLINGS AT DIFFERENT STOCKING WEIGHTS. | |
TWI458438B (en) | Fermentation and culture methods, plant fermentation extracts, plant fermentation extract powders, and plant fermentation extract complexes | |
KR20250032537A (en) | Composition for preventing, improving or treating dyslipidemia comprising fermented oats | |
KR20230133178A (en) | Breeding method of catfish comprising Rhus verniciflua STOKES trunk extract | |
WO2015005301A1 (en) | GELIDIUM AMANSII EXTRACT CONTAINING PGF2α | |
TW202348222A (en) | Myoblast proliferation promoting agent, composition for promoting myoblast proliferation, muscular atrophy inhibiting agent, and composition for inhibiting muscular atrophy | |
CN101987179A (en) | Red yeast rice generating component composition capable of resisting antibody lipogenesis and preparation method thereof | |
Ayyat et al. | EVALUATION OF POWERTOP® AS GROWTH ENHANCER OF NILE TILAPIA (Oreochromis siloticus) FINGERLINGS AT DIFFERENT STOCKING WEIGHTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |